A phase II study in newly diagnosed stage III/IV epithelial ovarian cancer evaluating carboplatin/taxol/pembrolizumab in patients receiving neoadjuvant chemotherapy followed by pembrolizumab maintenance with or without olaparib
Adding immunotherapy to standard chemotherapy may improve outcomes in advanced ovarian cancer, though more data are needed to confirm benefit.
This Gynecologic Oncology Phase 2 study assessed the addition of pembrolizumab to standard carboplatin/paclitaxel chemotherapy in newly diagnosed advanced epithelial ovarian cancer. The results inform whether PD-1 checkpoint inhibition can augment the standard of care in this high-recurrence malignancy.
What the study was
- Study design
- Phase 2 clinical trial
- Population
- Patients with newly diagnosed stage III/IV epithelial ovarian cancer
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Gynecologic oncology
Why it surfaced
Phase 2 trial data for pembrolizumab in frontline advanced ovarian cancer; a major high-unmet-need gynecologic malignancy with limited treatment advances beyond PARP inhibitors.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.